

ASX ANNOUNCEMENT



2 October 2025

Results disclosed in the Company's Unaudited Appendix 4E compared with the 2025 Annual Report

The Board of CONNEQT Health Limited (ASX: CQT) ("CONNEQT Health" or "the Company") refers to the Company's unaudited preliminary financial statements lodged with the ASX on 29 August 2025 (**Appendix 4E**) and the Company's 2025 Annual Report lodged with the ASX on 30 September 2025 (**Annual Report**).

The purpose of this announcement is to provide an explanation for the material differences between the results disclosed in the Appendix 4E and the results disclosed in the Annual Report. The variances are presented side by side in Appendix 1 to this announcement.

As discussed in the Appendix 4E, the Company's investment in inHealth Medical Services (inHealth) was subject to fair value adjustments resulting from the completion of an external valuation. On 30 September 2025, CONNEQT Health converted its Convertible Note investment into 630,000 shares of inHealth's common stock, resulting in 28.05% ownership of inHealth.

At the balance date of 30 June 2025, the total investment in inHealth was fair valued using a discounted cash flow (DCF) analysis to determine the recoverability of the assets. The revised investment in inHealth is carried at \$649,119 and is based on the expected final holding of 28.05%. The decreased carrying amount of the investment resulted in a \$4,722,153 fair value loss on investments in the year, an increase of \$4,104,112 compared to the Appendix 4E.

Post the release of the Appendix 4E, further analysis of inventory provisions was conducted. This resulted in an additional inventory provision of \$455,717, bringing the total inventory provision to \$824,502. The provision relates to raw materials inventory held for the manufacture of ATCOR products and was calculated based on the expected usage of the raw materials for the next three years and based on past consumption.

There is no indication that the raw material stock will become obsolete or unusable. The provision is a prudent measure and will be reassessed at each reporting date, based on updated expectations for the future utilisation of the inventory.

C O N N E Q T
Health

CONNEQT Health, LTD.
ASX: CQT

Info@conneqthealth.com
conneqthealth.com

Suite 301, 55 Lime St
Barangaroo 2000
Sydney, Australia

+61 2 9874 8761

For personal use only

Appendix 1

VARIANCES IN CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR YEAR ENDED 30 JUNE 2025

	2025 Annual Report	2025 Appendix 4E	Difference
		\$	\$
Sales revenue	3,551,284	3,551,284	-
Other income	2,554,226	2,731,340	(177,114) ⁴
Total revenue and other income	6,105,510	6,282,624	(177,114)
Cost of sales	(996,239)	(996,239)	-
Bad debts expense	(253,567)	(253,567)	-
Marketing and sales expense	(1,260,881)	(1,029,483)	(231,398) ³
Product development and regulatory expense	(2,214,942)	(2,214,942)	-
Occupancy expense	(282,982)	(283,514)	532 ⁵
Employee benefits expense	(9,628,254)	(9,628,254)	-
Share based payment expense	(645,810)	(645,810)	-
Administration expense	(2,638,999)	(2,638,999)	-
Interest expense	(662,466)	(662,466)	-
Inventory write-down expense	(824,502)	(368,785)	(455,717) ²
Amortisation expense	(103,729)	(103,197)	(532) ⁵
Fair value loss on investments	(4,722,153)	(618,041)	(4,104,112) ¹
Fair value (loss)/gain on financial assets and liabilities	(64,962)	(64,962)	-
Total expenses	(24,299,486)	(19,508,259)	(4,791,227)
Net loss before income tax expense	(18,193,976)	(13,225,635)	(4,968,341)
Income tax expense	-	-	-
Net loss for the period	(18,193,976)	(13,225,635)	(4,968,341)
Other comprehensive loss for the period, net of tax:			
Exchange differences on translating to the presentation currency	(53,087)	(55,477)	2,390 ⁴
Total comprehensive loss for the period attributable to members of the parent entity	(18,247,063)	(13,281,112)	(4,965,951)
Basic loss per share (cents)	(5.1)	(3.7)	(1.4)
Diluted loss per share (cents)	(5.1)	(3.7)	(1.4)

- 1 Due to fair value adjustments on the revaluation of inHealth
- 2 Due to the increase in inventory provision
- 3 Due to the accrual of additional marketing and sales expenses incurred in FY2025
- 4 Due to foreign exchange adjustments on financials assets and financial liabilities
- 5 Other immaterial adjustments

For personal use only

VARIANCES IN CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 30 JUNE 2025

	2025 Annual Report	2025 Appendix 4E	Difference
		\$	\$
ASSETS			
CURRENT ASSETS			
Cash and cash equivalents	2,433,097	2,433,097	-
Trade and other receivables	312,140	312,140	-
Inventory	1,985,749	2,441,466	(455,717) ²
Financial assets	-	4,486,773	(4,486,773) ¹
Other current assets	2,508,023	2,508,023	-
TOTAL CURRENT ASSETS	<u>7,239,009</u>	<u>12,181,499</u>	<u>(4,942,490)</u>
NON-CURRENT ASSETS			
Property, plant and equipment	837,063	837,063	-
Intangible assets	515,983	515,983	-
Financial assets	649,119	462,780	186,339 ¹
Other non-current assets	83,519	83,519	-
TOTAL NON-CURRENT ASSETS	<u>2,085,684</u>	<u>1,899,345</u>	<u>186,339</u>
TOTAL ASSETS	<u>9,324,693</u>	<u>14,080,844</u>	<u>(4,756,151)</u>
LIABILITIES			
CURRENT LIABILITIES			
Trade and other payables	4,090,087	3,861,079	229,008 ³
Unearned revenue	462,058	462,058	-
Provisions	460,080	460,080	-
Financial liabilities	1,728,244	1,747,452	(19,208) ⁴
Lease liabilities	191,504	191,504	-
Borrowings	1,079,267	1,079,267	-
TOTAL CURRENT LIABILITIES	<u>8,011,240</u>	<u>7,801,440</u>	<u>209,800</u>
NON-CURRENT LIABILITIES			
Provisions	12,141	12,141	-
Financial liabilities	381,680	381,680	-
Lease liabilities	286,125	286,125	-
TOTAL NON-CURRENT LIABILITIES	<u>679,946</u>	<u>679,946</u>	<u>-</u>
TOTAL LIABILITIES	<u>8,691,186</u>	<u>8,481,386</u>	<u>209,800</u>
NET ASSETS / NET (LIABILITES)	<u>633,507</u>	<u>5,599,458</u>	<u>(4,965,951)</u>
EQUITY			
Contributed equity	102,890,051	102,890,051	-
Reserves	2,628,122	2,625,732	2,390 ⁴
Accumulated losses	(104,884,666)	(99,916,325)	(4,968,341)
TOTAL EQUITY	<u>633,507</u>	<u>5,599,458</u>	<u>(4,965,951)</u>

- 1 Due to fair value adjustments on the revaluation of inHealth
- 2 Due to the increase in inventory provision
- 3 Due to the accrual of additional marketing and sales expenses incurred in FY2025
- 4 Due to foreign exchange adjustments on financials assets and financial liabilities

For personal use only

Approved by the Board of Directors and Released by the Company Secretary

- ENDS -

For more information, please contact:

Investor Relations

Rod Hinchcliffe
rod.hinchcliffe@mcpartners.com.au

Media Relations

Melissa Hamilton
melissa.hamilton@mcpartners.com.au

About CONNEQT HEALTH

CONNEQT Health's mission is to increase longevity through medical technology advancements in vascular health. The Company's suite of products includes medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders - all based on the Company's market-leading SphygmoCor® vascular biomarker technology. CONNEQT Health is listed on the Australian Stock Exchange ("ASX: CQT").

For personal use only